Global Tissue Diagnostics Market Growth, Trends & Forecasts (2017 - 2022)

The Global market for Tissue diagnostics is poised to reach $XX million by the end of 2020 growing at a CAGR of XX%. Tissue based diagnostics serves as one of the most important technique for cancer diagnosis. There is no other technology that can capture the disease insights and the parameters that factor into the patient outcomes. Tissue diagnostic aka Histopathology is the study of disease in tissue. Samples usually consist of pieces of tissue in various obtained by various methods. These include small biopsies, large specimens removed at surgery. Tissues generally enable personalized diagnosis & treatment.

Growth of personalized medicine, upsurge of cancer patients, increasing opportunities in digital pathology and high demand for companion & molecular diagnostics are the major factors driving the growth of the market. Limited customer base for tissue diagnostics, limited budget issues and regulatory framework issues are the factors hindering the growth of the market.

The Tissue diagnostic market can be segmented on the basis of By Technology (Immunohistochemistry, In situ hybridization, Digital pathology and workflows, Special staining), By Product (Instruments, Consumables), By Application (Prostrate Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Skin Cancer, Cervical Cancer, Lymphoma, Gastric Cancer), By End User (Hospitals & Clinics, CRO, Research Labs, Pharmaceutical firms) and By Geography.

Tissue tests will spearhead the IVD industry revenue in the future. Currently, North America is the largest market in the world followed by Europe. This can be attributed to the increased awareness about the potential benefits of diagnostics among the population. APAC is the fastest growing segment. The key players for this market are Abbott Laboratories, Roche, Sigma Aldrich, Life Technologies, Danaher Corporation, Agilent Technologies, Biogenex Laboratories, Cell Signalling Technology, 3DHISTECH, Affymetrix, Cancer Genetics,Inc., Definiens, Genomic Health, Inc.

What the report offers

Market analysis for the Global market for Vital Signs Monitoring, with region specific assessments and competition analysis on global and regional scales
Market definition along with the identification of key drivers and restraints
Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale
Extensively researched competitive landscape section with profiles of major companies along with their market shares
Identification and analysis of the macro and micro factors that affect Global market for Vital Signs Monitoring on both global and regional scales
A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information
A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market
Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped

1. Introduction

1.1 Report Description

1.2 Research Methodology

2. Key Findings

3. Executive Summary

4. Market Dynamics

4.1 Market Segmentation

4.2 Market Drivers

4.2.1 Growth of personalized medicine boosting the market growth

4.2.2 Upsurge of Cancer patients booming the market growth

4.2.3 Increasing opportunities in Digital Pathology

4.2.4 High demand for companion & molecular diagnostics

4.3 Market Restraints

4.3.1 Limited customer base for tissue diagnostics

4.3.2 Limted budget hindering the growth of the market

4.3.3 Regulatory framework issues

5. Global Market Segmentation

5.1 By Technology

5.1.1 H&E Slide Staining

5.1.2 Immunohistochemistry (IHC) IHC Detection Systems IHC Primary Antibodies Research IHC Detection Others

5.1.3 In-Situ Hydbridization (ISH) ISH Detection Systems Research ISH Detection ISH Probes Others

5.1.4 Special Stains

5.1.5 Digital Pathology Dermatopathology Lung Pathology Colorectal Pathology Breast Pathology Hematopathology Prostate Pathology Cervical Cancer Diagnostics

5.2 By Platform

5.2.1 High Throughput Scanning (HTS)

5.2.2 Brightfield Scanning

5.2.3 H&E Staining

5.2.4 Image Management

5.2.5 IHC/ISH Staining

5.2.6 Specimen Workflow

5.2.7 Speical Stains

5.2.8 Research IHC/ISH

5.3 By Application

5.3.1 Prostrate Cancer

5.3.2 Lung Cancer

5.3.3 Colorectal Cancer

5.3.4 Breast Cancer

5.3.5 Skin Cacner

5.3.6 Cervical Cancer

5.3.7 Lymphoma

5.3.8 Gastric Cancer

5.3.9 Others

5.4 By Product

5.4.1 Instruments

5.4.2 Reagents

5.4.3 Others

5.5 By End User

5.5.1 Research Labs

5.5.2 CRO

5.5.3 Hospitals

5.5.4 Pharmaceuticals

5.5.5 Others

5.6 By Geography

5.6.1 North America US Canada Mexico

5.6.2 Europe UK Germany France Spain Italy Rest of Europe

5.6.3 Asia Pacific China Japan India South Korea Rest of Asia Pacific

5.6.4 Rest of the World

6. Competitive Landscape

6.1 Mergers & Acquisitions

6.2 Agreements, Collaborations & Partnerships

6.3 New Product Launches

6.4 Recommendations to new market players

7. Company Profiles

7.1 Abbott Laboratories

7.2 Roche

7.3 Sigma Aldrich

7.4 Life Technologies

7.5 Danaher Corporation

7.6 Agilent Technologies

7.7 Biogenex Laboratories

7.8 Cell Signalling Technology


7.10 Affymetrix

7.11 Cancer Genetics,Inc.

7.12 Definiens

7.13 Genomic Health, Inc.

8. Appendix

8.1 Abbreviations

8.2 Sources

8.3 Bibliography

8.4 Disclaimer

Content are not available

Choose License Type